In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma

Pavan Kumar Naraharisetti, Benjamin Yung Sheng Ong, Jing Wei Xie, Timothy Kam Yiu Lee, Chi Hwa Wang, Nikolaos V. Sahinidis

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Drug-releasing implants delivering chemotherapeutic and radio-sensitizing agents are beginning to play a major role in the post-surgical eradication of residual glioma in the brain. Benefits from early arresting of tumor growth and tumor recovery dynamics stress the impact of drug release profiles of the implants on the efficacy of the treatment. This paper examines responses of BALB/c nude mice, bearing C6 glioma tumors subcutaneously, to treatments by PLGA microspheres, microparticles and discs-delivering Paclitaxel and Etanidazole. The experimental results are used to correlate the efficacy of treatment to in vitro release profiles from the various formulations. Our study demonstrates that radio-sensitizing effects during irradiation could be achieved by double burst profiles from Etanidazole-loaded discs, when compared to controls 17 days after implantation despite the short half-life of Etanidazole (1.4 h) in vivo. These results also showed inhibited tumor growth on tumor volumes of 59%, 65% and 70% over the blank placebo groups after 21 days of tumor growth for spray-dried microspheres, electrohydrodynamic atomization microparticles and spray-dried discs, respectively.

Original languageEnglish (US)
Pages (from-to)886-894
Number of pages9
JournalBiomaterials
Volume28
Issue number5
DOIs
StatePublished - Feb 1 2007

Fingerprint

Etanidazole
Paclitaxel
Glioma
Tumors
Neoplasms
Radio
Microspheres
Drug Implants
Growth
Bearings (structural)
Therapeutics
Electrohydrodynamics
Tumor Burden
Nude Mice
Atomization
Half-Life
Pharmaceutical Preparations
Placebos
Brain
Irradiation

Keywords

  • Drug delivery
  • Etanidazole
  • Glioma
  • In vivo
  • Paclitaxel
  • Subcutaneous

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma. / Kumar Naraharisetti, Pavan; Yung Sheng Ong, Benjamin; Wei Xie, Jing; Kam Yiu Lee, Timothy; Wang, Chi Hwa; Sahinidis, Nikolaos V.

In: Biomaterials, Vol. 28, No. 5, 01.02.2007, p. 886-894.

Research output: Contribution to journalArticle

Kumar Naraharisetti, Pavan ; Yung Sheng Ong, Benjamin ; Wei Xie, Jing ; Kam Yiu Lee, Timothy ; Wang, Chi Hwa ; Sahinidis, Nikolaos V. / In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma. In: Biomaterials. 2007 ; Vol. 28, No. 5. pp. 886-894.
@article{136486f7fc2b4f898e75bcd35d710d8f,
title = "In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma",
abstract = "Drug-releasing implants delivering chemotherapeutic and radio-sensitizing agents are beginning to play a major role in the post-surgical eradication of residual glioma in the brain. Benefits from early arresting of tumor growth and tumor recovery dynamics stress the impact of drug release profiles of the implants on the efficacy of the treatment. This paper examines responses of BALB/c nude mice, bearing C6 glioma tumors subcutaneously, to treatments by PLGA microspheres, microparticles and discs-delivering Paclitaxel and Etanidazole. The experimental results are used to correlate the efficacy of treatment to in vitro release profiles from the various formulations. Our study demonstrates that radio-sensitizing effects during irradiation could be achieved by double burst profiles from Etanidazole-loaded discs, when compared to controls 17 days after implantation despite the short half-life of Etanidazole (1.4 h) in vivo. These results also showed inhibited tumor growth on tumor volumes of 59{\%}, 65{\%} and 70{\%} over the blank placebo groups after 21 days of tumor growth for spray-dried microspheres, electrohydrodynamic atomization microparticles and spray-dried discs, respectively.",
keywords = "Drug delivery, Etanidazole, Glioma, In vivo, Paclitaxel, Subcutaneous",
author = "{Kumar Naraharisetti}, Pavan and {Yung Sheng Ong}, Benjamin and {Wei Xie}, Jing and {Kam Yiu Lee}, Timothy and Wang, {Chi Hwa} and Sahinidis, {Nikolaos V.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.biomaterials.2006.09.044",
language = "English (US)",
volume = "28",
pages = "886--894",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma

AU - Kumar Naraharisetti, Pavan

AU - Yung Sheng Ong, Benjamin

AU - Wei Xie, Jing

AU - Kam Yiu Lee, Timothy

AU - Wang, Chi Hwa

AU - Sahinidis, Nikolaos V.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Drug-releasing implants delivering chemotherapeutic and radio-sensitizing agents are beginning to play a major role in the post-surgical eradication of residual glioma in the brain. Benefits from early arresting of tumor growth and tumor recovery dynamics stress the impact of drug release profiles of the implants on the efficacy of the treatment. This paper examines responses of BALB/c nude mice, bearing C6 glioma tumors subcutaneously, to treatments by PLGA microspheres, microparticles and discs-delivering Paclitaxel and Etanidazole. The experimental results are used to correlate the efficacy of treatment to in vitro release profiles from the various formulations. Our study demonstrates that radio-sensitizing effects during irradiation could be achieved by double burst profiles from Etanidazole-loaded discs, when compared to controls 17 days after implantation despite the short half-life of Etanidazole (1.4 h) in vivo. These results also showed inhibited tumor growth on tumor volumes of 59%, 65% and 70% over the blank placebo groups after 21 days of tumor growth for spray-dried microspheres, electrohydrodynamic atomization microparticles and spray-dried discs, respectively.

AB - Drug-releasing implants delivering chemotherapeutic and radio-sensitizing agents are beginning to play a major role in the post-surgical eradication of residual glioma in the brain. Benefits from early arresting of tumor growth and tumor recovery dynamics stress the impact of drug release profiles of the implants on the efficacy of the treatment. This paper examines responses of BALB/c nude mice, bearing C6 glioma tumors subcutaneously, to treatments by PLGA microspheres, microparticles and discs-delivering Paclitaxel and Etanidazole. The experimental results are used to correlate the efficacy of treatment to in vitro release profiles from the various formulations. Our study demonstrates that radio-sensitizing effects during irradiation could be achieved by double burst profiles from Etanidazole-loaded discs, when compared to controls 17 days after implantation despite the short half-life of Etanidazole (1.4 h) in vivo. These results also showed inhibited tumor growth on tumor volumes of 59%, 65% and 70% over the blank placebo groups after 21 days of tumor growth for spray-dried microspheres, electrohydrodynamic atomization microparticles and spray-dried discs, respectively.

KW - Drug delivery

KW - Etanidazole

KW - Glioma

KW - In vivo

KW - Paclitaxel

KW - Subcutaneous

UR - http://www.scopus.com/inward/record.url?scp=33750511549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750511549&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2006.09.044

DO - 10.1016/j.biomaterials.2006.09.044

M3 - Article

C2 - 17067667

AN - SCOPUS:33750511549

VL - 28

SP - 886

EP - 894

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 5

ER -